Refine Your Search

  • Solutions

  • Therapeutic Areas

  • Resource Type

FDA Renews and Expands its Portfolio of Simcyp Simulator (PBPK) Licenses

PRINCETON, NJ – Nov. 14, 2017 – Certara today announced that the US Food and Drug Administration has greatly expanded its use of Certara’s PBPK Simcyp Population-based Simulator and its Pediatric and Cardiac Safety Simulators. Under the new agreement, FDA has almost tripled its number of licenses, equipping its M&S review team with almost 60 PBPK licenses.

Solution: PBPK Modeling & Simulation
More Info

Kyowa Hakko Kirin Joins Certara’s Simcyp Consortium

PRINCETON, NJ – Sept. 13, 2017 – Certara today announced that Kyowa Hakko Kirin Co., Ltd. has joined the Simcyp Consortium and licensed the Simcyp Population-based Simulator. Kyowa Hakko Kirin is the 36th leading biopharmaceutical company and the 11th Japanese pharmaceutical company to join the Consortium.

More Info

Paper Shows How Viral Kinetic Modeling Increases Influenza Knowledge & Advances Drug Development

PRINCETON, NJ – Sept. 6, 2017 – Certara today announced that its comprehensive influenza viral kinetic modeling review has just been published in Current Pharmacology Reports. As the number of drug-resistant influenza strains grows, researchers are searching for better ways to develop safer, more effective anti-viral drugs. Viral kinetic modeling, in combination with PK/PD modeling, is proving to be a fruitful resource.

More Info
Learn More LinkedIn Twitter Facebook Email Subscribe to the Blog